FAST NEWS: Ascletis Pharma Soars after Expanding Production of Covid-19 Tablets
The latest: Ascletis Pharma Inc. (1672.HK) announced the expansion of its annual production capacity of ritonavir oral tablets, a component of oral direct-acting Covid-19 drug paxlovid, to 100 million tablets,…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
- Innogen Pharma jostles for a slice of the weight-loss market
- As Covid drug cash dwindles, Vigonvita targets new remedies
